Welcome to our dedicated page for Bio-Path Hldgs SEC filings (Ticker: BPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Path Holdings, Inc. (BPTH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain complex documents. As a clinical-stage biotechnology company, Bio-Path uses its SEC reports to describe the status of its DNAbilize® RNAi nanoparticle platform, clinical trials for prexigebersen (BP1001), BP1001-A, BP1002, and BP1003, and the financial resources supporting these programs.
In annual reports (Form 10-K) and quarterly reports (Form 10-Q), Bio-Path discusses its clinical-stage pipeline, research and development expenses, operating losses, and going-concern risks. These filings also outline the company’s strategy to generate drug candidates from DNAbilize® and its need for additional capital. Notification filings such as Form 12b-25 explain delays in periodic reports and can reference management changes or other factors affecting reporting timelines.
Current reports on Form 8-K are especially important for BPTH, as they document material events such as leadership changes, board resignations, operational pauses, financing efforts, and strategic evaluations. One 8-K describes a company-wide operational pause, furloughs of most employees, and the possibility that Bio-Path may need to delay or eliminate programs, license or dispose of assets on less favorable terms, or potentially liquidate and dissolve the company if it cannot raise capital. Other 8-K filings detail changes in executive roles and board composition, as well as plans to seek financing and review the biotech portfolio.
The Form 25 filing for Bio-Path records the removal of its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act, a key event in the company’s trading history. Through these and other filings, investors can follow developments related to listing status, capital structure, and operational plans.
Stock Titan’s interface surfaces these documents in chronological order and applies AI-generated highlights to help readers quickly identify disclosures about clinical progress, financial condition, going-concern language, and corporate actions. Users can review Forms 10-K, 10-Q, 8-K, 12b-25, and Form 25 to build a detailed picture of Bio-Path’s regulatory and financial history, as well as its risk profile as a clinical-stage biotech issuer.
Bio-Path Holdings, Inc. reports a third-quarter 2025 net loss of
Cash fell to
The company has furloughed most employees and instituted a company‑wide operational pause to conserve capital, while relying on dilutive financings and high‑cost promissory notes that carry default penalties and conversion features. Notes issued in March 2025 are already in default and an April 2025 note defaulted after quarter end, creating a derivative liability of
Bio-Path Holdings, Inc. filed a Form 12b-25 to notify the SEC and investors that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states it is still compiling the necessary information for the quarterly report and that all information has not yet been received due to a change in management. Bio-Path indicates it expects to file the Form 10-Q within the permitted grace period after the original due date.
Bio-Path Holdings (BPTH) filed an 8-K announcing a board change and financing plans. The Board accepted the resignation of Director Douglas Morris, delivered electronically on November 4, 2025 and accepted on November 13, 2025.
The company is seeking financing to support a planned turnaround that it anticipates will include updating its finance team, engaging new PCAOB auditors, hiring investment bankers to review its biotech portfolio for sale or partnerships, and pursuing strategic mergers and acquisitions. The company cautions that there can be no assurances of success. If capital cannot be raised, the company states there is substantial doubt about its ability to continue as a going concern and to remain listed on the OTC Markets or other public trading platforms.
Bio-Path Holdings (BPTH)October 22, 2025, the Board appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board. The Board also accepted the resignation of Douglas Morris as Interim CEO and Interim CFO; he remains on the Board. In addition, Paul Aubert resigned as a Director.
This consolidates executive leadership under one individual while maintaining board continuity through Mr. Morris’s continued service. The filing does not include financial results or strategic updates, focusing solely on governance and leadership transitions.
On 20–22 June 2025, Bio-Path Holdings, Inc. (BPTH) disclosed a sequence of leadership departures and an immediate operational shutdown driven by acute liquidity constraints, according to its Form 8-K filing.
Founder Peter H. Nielsen resigned from every executive position—President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer—as well as Chairman and director roles. Directors Heath Cleaver and Aline Sherwood also stepped down; both stated their decisions were not the result of disagreements with the Company or Board.
The remaining directors appointed Douglas P. Morris as Chairman with no compensatory changes. Concurrently the Board instituted a company-wide operational pause, furloughing most employees and suspending the majority of drug-development activities to conserve capital while it searches for new financing.
The filing reiterates prior warnings: without additional capital, Bio-Path may have to scale back or eliminate development programs, dispose of assets on unfavorable terms, or proceed to liquidation and dissolution. There is no assurance of securing funding on acceptable terms, if at all.
Overall, the 8-K signals elevated going-concern risk, abrupt leadership vacuum and potential value erosion for shareholders.
FAQ
What is the current stock price of Bio-Path Hldgs (BPTH)?
What is the market cap of Bio-Path Hldgs (BPTH)?
